The Central Venous Catheter Related Complications in Critically Ill Patients
Launched by ZHUJIANG HOSPITAL · Feb 12, 2019
Trial Information
Current as of May 05, 2025
Unknown status
Keywords
ClinConnect Summary
A prospective clinical trial is conducted. Five hundred participants who need to place central venous catheters admit to the Department of Critical Care Medicine of Zhujiang Hospital,Southern Medical University from February 2019. Ultrasound is used for screening catheter-related thrombosis, and catheter-related infections are diagnosed according to the Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infections. The primary outcome is the incidence of catheter-related thrombosis and catheter-related infections. The primary exposure factors are age, gender, APAC...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \> 18 years old and \<80 years old;
- • Central venous catheter is required to be placed through the internal jugular vein, subclavian vein or femoral vein;
- • Catheter placement is estimated to be ≥ 72 hours.
- Exclusion Criteria:
- • The central venous catheter has been placed before entering the department;
- • There is obvious trauma or infection at the site of implantation;
- • There is already a blood vessel thrombus in the site before implantation;
- • Recently, deep vein thrombosis or catheter-related thrombosis has occurred.
About Zhujiang Hospital
Zhujiang Hospital, affiliated with the Southern Medical University in Guangzhou, China, is a leading clinical research institution dedicated to advancing medical science and improving patient care through rigorous clinical trials. With a strong commitment to ethical standards and patient safety, the hospital boasts a multidisciplinary team of experienced researchers and healthcare professionals. Its state-of-the-art facilities enable the execution of innovative studies across various therapeutic areas, contributing valuable insights to the global medical community. Zhujiang Hospital aims to foster collaboration with academic institutions, pharmaceutical companies, and regulatory bodies to ensure the successful development of new therapies and enhance treatment options for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guangdong, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials